Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. (KPRX) is a clinical-stage specialty pharmaceutical company focused on developing therapies for retinal diseases. The filing is an Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company operates in a single segment and is classified as a smaller reporting company and non-accelerated filer.
Key assets include:
- KIO-301: A "photoswitch" small molecule for retinitis pigmentosa (RP). The company partnered with Théa Open Innovation (TOI) in January 2024 for global rights (excluding Asia). The Phase 2 ABACUS-2 trial is currently enrolling.
- KIO-104: A DHODH inhibitor for retinal inflammation (e.g., Diabetic Macular Edema). The Phase 2 KLARITY trial began enrollment in Q2 2025.
- KIO-101: A topical eye drop for ocular autoimmune diseases; the company is seeking a strategic partner.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $0 | $16.02 million |
| Net Loss / Income | $(10.84) million | $3.59 million |
| Operating Expenses | $12.83 million | $11.51 million |
| Research & Development (Gross) | $10.78 million | $7.84 million |
| Collaboration Credits (Reimbursements) | $(7.07) million | $(2.95) million |
| In-Process R&D Impairment | $4.62 million | $2.01 million |
| Cash and Cash Equivalents | $8.70 million | $3.79 million |
| Short-Term Investments | $8.39 million | $23.00 million |
| Total Liquidity (Cash + Investments) | $17.09 million | $26.79 million |
| Accumulated Deficit | $(154.22) million | $(143.38) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped from $16.02 million in 2024 to $0 in 2025. The 2024 revenue was driven by a $16 million upfront payment from the TOI collaboration agreement, which was recognized in Q1 2024. No similar upfront payments were recognized in 2025.
- Net Loss vs. Income: The company swung from a net income of $3.59 million in 2024 to a net loss of $10.84 million in 2025, primarily due to the absence of the TOI upfront revenue and increased operating costs.
- Impairment Charge: A $4.62 million impairment charge was recorded in 2025 related to the KIO-104 asset. Management stated this was driven by a decline in market capitalization and stock price rather than adverse clinical progress or changes in development timelines.
- Increased R&D Spend: Gross R&D expenses increased by $2.94 million to $10.78 million, largely due to increased spending on KIO-301 activities (reimbursed by TOI) and clinical trial costs.
- Collaboration Credits: Reimbursements from TOI for KIO-301 R&D expenses increased significantly to $7.07 million in 2025, compared to $2.95 million in 2024.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash and short-term investments ($17.1 million) are sufficient to fund planned operations into late 2027. The company does not anticipate an immediate need to raise capital but will require additional funding to complete development and commercialization efforts.
Strategic Developments:
- Senju Option: In May 2025, Kiora entered an exclusive option agreement with Senju Pharmaceutical for KIO-301 rights in Asia (Japan/China), receiving a $1.25 million non-refundable upfront payment (recorded as deferred revenue).
- Credit Facility: A $10 million revolving credit line with UBS was established in March 2025. It was utilized and repaid during the year, with a zero balance as of year-end.
Risks and Contingencies:
- Capital Needs: The company has incurred significant losses since inception and expects to continue doing so. Failure to raise additional capital could force delays or termination of programs.
- Dependence on Partners: Success depends heavily on TOI for KIO-301 development and commercialization outside Asia. TOI controls the development strategy and could de-prioritize the asset.
- Regulatory and Clinical Risk: No products are approved. Clinical trials (ABACUS-2 and KLARITY) are ongoing; failure to demonstrate safety/efficacy would materially harm the business.
- Stock Price Volatility: The company faces risks related to Nasdaq listing requirements, including a proposed minimum Market Value of Listed Securities (MVLS) of $5 million.
Investor Verification Checklist
- Runway Confirmation: Verify the "late 2027" cash runway estimate against current burn rates and potential acceleration of clinical trial costs.
- Impairment Rationale: Review the specific valuation assumptions used for the $4.62 million KIO-104 impairment to confirm it was purely market-driven and not indicative of underlying asset weakness.
- TOI Reimbursement Terms: Confirm the scope of reimbursable expenses under the TOI agreement and the timing of cash receipts to ensure they align with cash flow projections.
- Senju Option Exercise: Monitor the timeline for the ABACUS-2 Phase 2 topline data, which triggers the option exercise period for the Senju agreement.
- Nasdaq Compliance: Track the Market Value of Listed Securities (MVLS) to ensure compliance with current and proposed Nasdaq Capital Market listing standards.